
Introduction
Tukysa (generic name: tucatinib) is a targeted cancer therapy used to treat HER2-positive breast cancer that is locally advanced or metastatic (spread to other parts of the body). It is especially indicated for patients whose cancer has progressed despite prior therapies. Tucatinib works by blocking the HER2 protein, which fuels the growth of cancer cells, thereby helping slow disease progression.
In addition to breast cancer, the U.S. FDA granted accelerated approval in January 2023 for tucatinib in combination with trastuzumab for the treatment of RAS wild-type HER2-positive metastatic colorectal cancer that has progressed after standard chemotherapy.
Tukysa is supplied as oral tablets and is a prescription-only medication, meaning it can only be dispensed with a valid doctor’s prescription. Patients in India who need to access this medicine can do so legally via named-patient import programs, supported by authorized facilitators.
Tucatinib (Tukysa) is an important therapy for patients with HER2-positive breast cancer and colorectal cancer, offering hope when other treatments have failed. While the tukysa price in India may vary depending on sourcing and logistics, patients can legally buy tucatinib in India through named-patient import programs with the right documentation.
For patients and doctors exploring tucatinib availability in India, working with authorized facilitators ensures: Genuine and reliable supply from international sources. 100% transparency in cost and process. Compliance with legal import requirements
Pricing
The Tukysa price in India varies depending on:
Dosage requirements and treatment duration.
The country of origin (USA, Canada, Europe, or Australia).
Import duties, handling, and logistics costs.
As the drug is not yet manufactured or widely marketed in India, the price can only be determined once sourcing and shipping details are finalized. Patients who want to buy tucatinib in India are advised to work with verified import facilitators who can provide transparent pricing, ensure authenticity, and guide them through the legal process.
Since Tukysa is often imported on a named-patient supply (NPS) basis, the costs may be higher than locally available alternatives, but this process guarantees genuine supply and compliance with Indian law. Patients are strongly advised against relying on unverified sources that may supply counterfeit or unsafe products.
Access Steps
Patients or hospitals seeking to import tucatinib in India must follow a regulated process to ensure the medicine is dispensed safely and legally.
- Required Documentation
-
- A valid prescription from a qualified oncologist.
- Patient’s diagnostic reports confirming HER2-positive breast cancer or other approved indications.
- Government-issued ID proof of the patient.
- An import permit (if required by Indian authorities).
- Application Process
-
- The application is generally filed under Form 12A for personal use, along with the prescription and supporting medical documents. Import permits are issued in the patient’s name, ensuring the medicine is used only for the intended recipient.
- Order Confirmation
-
- Orders are confirmed once all documents are received and verified. This ensures compliance with Indian drug regulations.
- Distribution Across India
-
- Tukysa (tucatinib) can be made available in major cities including Delhi, Mumbai, Kolkata, Bangalore, Hyderabad, Chennai, Ahmedabad, Pune, Jaipur, Lucknow, Kochi, Chandigarh, and more. Delivery is handled only after verification of prescriptions to maintain patient safety
For patients seeking Tucatinib (Tukysa) in India, understanding how to access it safely and legally can feel stressful. Questions about availability, cost, and the proper process to obtain it are common, and having the right guidance makes the process much easier.Trusted platforms like 24/7 QualityMeds provide step-by-step guidance to help patients understand the process, check costs, and access the medication safely. You can get personalized support by reaching out at +91 99679 79080. With the right guidance, patients can confidently explore legal options to obtain Tucatinib and continue their treatment journey.